Osteoporosis Research Ltd
The Team
Who We Are
Prof John A. Kanis
Founder & CEO
John A. Kanis is Emeritus Professor in Human Metabolism, and Director of the Centre for Metabolic Bone Diseases (Formerly WHO Collaborating Centre) University of Sheffield, UK and Professorial Fellow at Australian Catholic University (Melbourne, Australia). He is Honorary President of the International Osteoporosis Foundation, member of its Committee of Scientific Advisors and Chairman of the Working Group on Epidemiology and Quality of Life.
Prof. Kanis’s research interests are largely related to disorders of skeletal metabolism including osteoporosis, sarcopenia, Paget’s disease of bone, hyperparathyroidism, renal osteodystrophy and neoplasia affecting the skeleton. Contributions to research include cell biology, histomorphometry of bone, assessment and treatment of bone disorders, guideline development, health technology assessment, epidemiology, regulatory affairs and health economics. He is the Editor in Chief of Osteoporosis International and Archives of Osteoporosis and serves on the editorial board of several journals. He is the author of more than 1000 papers, chapters and books on bone disease and metabolism. His current major interest is in the development of risk assessment algorithms and the formulation of practice guidelines in many regions of the world.
Prof Eugene McCloskey
Director
Eugene McCloskey is Professor of Adult Bone Diseases, Mellanby Centre for Musculoskeletal Research, University of Sheffield, and Director of the Medical Research Council Versus Arthritis Centre for Integrated research in Musculoskeletal Ageing. His roles include past President of the Bone Research Society, UK, Chair of the Royal Osteoporosis Society Research Academy Effectiveness Working Group, Board Member of the IOF and ESCEO, and a past member of the ECTS Clinical Practice Action Group. As a member of the National Osteoporosis Guidance Group (NOGG) in the UK, he has helped integrate fracture risk assessment with clinical management. He has published approximately 460 original articles in research areas encompassing the treatment of cancer-associated osteolysis, osteoporosis and Paget’s disease, vertebral fracture definition, non-invasive skeletal assessments and the development of the FRAX® fracture risk assessment tool.
Roo Kanis - Buck
Director
Roo Kanis-Buck is co-owner and Director at ORL. She has over 25 years’ experience in the world of life sciences, diagnostic and pharmaceutical industry and has a broad range of pharmaceutical development experience, with strong project management and planning skills. She has overseen global pharmaceutical development programmes both in therapeutic and diagnostic fields. She has experience with FDA, EMA, MHRA and other European regulatory agencies. Roo has held several programme management positions and consults for a variety of clients via RApport Global Strategic Services. Most recently Roo is Programme Director for Blue Earth Diagnostics, overseeing global development of their PET imaging tracer in the area of brain metastases. Previously Roo worked at the boutique CRO Simbec Orion as part of their Regulatory & Ethics team. Prior to a career break to raise her daughters, Roo worked at Scottish company ProStrakan Group Plc where she was employed as Global Business Account & Project Manager. Prior its merger with Proskelia, Roo worked for Strakan Ltd as a Global Project Manager in drug development, Stratford HC Ltd, Andover as a Project Assistant and at the metabolic bone unit in Sheffield University as a Clinical Trials Technician.